Complimentary Webinars

Health Literacy

Watch now >

Health literacy has two sides. For the patient, their level of health literacy defines how they can obtain, process, and understand health information and services needed to make appropriate health decisions.

However, it is the responsibility of the communicator to share information in a way that is understandable.

In this webinar we will discuss the importance of applying health literacy best practices throughout the lifecycle of clinical trials and how doing so benefits everyone involved in clinical trials including the trial participants, investigators, sponsors, and the IRB/ECs.

• What health literacy is and how it is assessed. Levels of health literacy worldwide.
• What are the risks arising from low levels of health literacy?
• How health literacy helps patients make informed health decisions.
• How can applying health literacy best practices for clear communication enhance participant understanding, trust, and satisfaction?
• Why health literacy is important in clinical trials.
• How can clear communication help improve clinical trial equity and data integrity?

Moderator:
Kasra Shakeri-Nejad, Global Head Clinical Pharmacology, Translational Medicine, Novartis Institutes for Biomedical Research

Speakers:
Catina O'Leary, President & CEO, Health Literacy Media
Jessica Valencia, Director of Innovation in Patient Engagement, Novartis Institutes for Biomedical Research NIBR, Translational Medicine, Patient Insights & Experience
John H Powers, Physician/Investigator and Professor of Clinical Medicine, George Washington University School of Medicine, Adjunct Professor at the University of Maryland School of Pharmacy

Sponsored by Novartis Institutes for BioMedical Research (NIBR)

The Promise of Next Generation Clinical Trials

Watch now >

With this discussion of ‘Next Generation Clinical Trials”, we continue the series of Translational Medicine webinars. We focus on solutions to the challenge of learning more from clinical trials and meeting patient needs faster.

Join our discussion with experts on:

• What we mean by Next Generation Trials.
• Why there is pressure to change how trials are done.
• The advantages for both patient and sponsor. The exploration-exploitation trade off.
• How this work connects with access and equity aims in clinical research.
• How Next Generation Trials in Translational Medicine can speed the delivery of new drugs.
   

Moderator: 
Sarah Hemsley, Innovation Project Manager, Novartis Institutes for BioMedical Research (NIBR)

Speakers: 
Darcy Forman, Chief Delivery Officer, Science 37
Sam Hariry, Global Head, Clinical Innovation, Novartis Institutes for BioMedical Research (NIBR)
Brian Tseng, Board-certified MD/PhD Pediatric Neurologist

Sponsored by Novartis Institutes for BioMedical Research (NIBR)

Immunogenicity for Biotherapeutics in Drug Development

Watch now >

With this discussion on ‘Immunogenicity of Biotherapeutics’, we continue the series of webinars highlighting solutions to challenges in Translational Medicine.

Join us as we seek to clarify some of the myths around immunogenicity; factors that contribute to the identification, classification, and prediction of immunogenicity risks; and how to measure immune responses to biotherapeutics. An important goal is to understand the impact of immunogenicity on the clinical efficacy and safety of drugs - including how to mitigate and manage such impacts during the process of developing biotherapeutics. 

The panel of Translational Medicine experts from big pharma, biotech and academia will discuss:   

• What is the general understanding of the concepts that underlie immunogenicity?. 
• Why are robust, sensitive, and specific anti-drug-antibody (ADA) assays essential?
• Why is early risk assessment and mitigation key?
• How should we evaluate and interpret immunogenicity data from pre-clinical and clinical studies?
• What are the clinical risk mitigation and management strategies that can be employed?

Moderator: 
Claire Bonal, MD, PhD, Translational Medicine Expert, Novartis Institutes for Biomedical Research (NIBR)

Speakers: 
Jim McNally, Chief Scientific Officer, BioAgilytix
Hannah Morgan, Senior Principle Scientist, Novartis Pharma AG Translational Medicine
Professor Marc Pallardy, Head of the Department of Toxicology, Faculty of Pharmacy, University of Paris-Saclay

Sponsored by Novartis Institutes for BioMedical Research (NIBR)

Physician-Scientists in the Delivery of Translational Medicine

Watch now >

In the first of a series of webinars discussing current thinking on solutions to the challenges in Translational Medicine, we review the roles and potential contributions of Physician-Scientists. How organizations can optimize the contributions of Physician-Scientists and how Physician-Scientists can achieve their visions of better patient care.

Physician-Scientists, whether in academia or industry, work within a range of operational structures and cultures. What do they need to succeed, what is expected of them and how can the multiple objectives of patients and healthcare providers be met? 

The panel of Translational Medicine experts from big pharma, start-up biotech and academia will discuss: 

• Alternative views of what Translational Medicine is
• How Physician-Scientists contribute and the most effective structures and teams for undertaking the work
• The emerging speciality of ‘Translational Medicine’: roles and career structures
• The resources (expertise, equipment, services, and finance) Physician-Scientists need to optimize their contributions
• Continuing Professional Education for the Physician-Scientist – time is not an infinite resource
• Moving from academia to big pharma/biotech: when, why and what to expect

Moderator: 
Michael Badman, MBBS DPhil FRCP, Translational Medicine Expert, Novartis Institutes for Biomedical Research (NIBR)

Speakers: 
Ronenn Roubenoff, Global Head, Translational Medicine Discovery & Profiling, Novartis Institutes for Biomedical Research (NIBR)
Dr. Aoife Brennan, President & CEO, Synlogic
Dr. Garret FitzGerald, Professor of Medicine and Pharmacology; McNeil Professor in Translational Medicine and Therapeutics; Director, Institute for Translational Medicine & Therapeutics, Perelman School of Medicine, University of Pennsylvania

⠀⠀⠀

Sponsored by Novartis Institutes for BioMedical Research (NIBR)